Ivosidenib (IVO) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment of a phase 1 dose escalation and expansion study Meeting Abstract
| Authors: | DiNardo, C. D.; Foran, J. M.; Watts, J. M.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A. S.; Stone, R. M.; Patel, P. A.; Roboz, G. J.; Arellano, M. L.; Erba, H. P.; Pigneux, A.; Stuart, R. K.; Thomas, X.; Uy, G. L.; Oluyadi, A.; Lemieux, I. R.; Liu, H.; Wu, B.; Winkler, T.; Garcia-Manero, G.; Sallman, D. A. |
| Abstract Title: | Ivosidenib (IVO) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment of a phase 1 dose escalation and expansion study |
| Meeting Title: | 8th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | clinical trial; targeted therapy; mds; isocitrate dehydrogenase 1; myelodysplastic; syndromes; ivosidenib |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 20 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Sep 9-12 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-09-01 |
| Start Page: | S321 |
| Language: | English |
| ACCESSION: | WOS:000564055100358 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(20)30977-0 |
| Notes: | Meeting Abstract: MDS-265 -- Due to COVID-19 pandemic, the conference was held virtually -- Source: Wos |
